Testing

Fewer than half the people found to have colorectal cancer are diagnosed at an early stage, when treatment is most effective. New therapies can reduce tumor size and prolong life, but they can also be costly and not work as intended. The results and interpretations from our laboratories provide clinically actionable results to guide treatment selection, ensuring every patient receives the medication most appropriate for care. In addition to guiding treatment, our testing also assesses risk for developing hereditary cancer syndrome.

By Alyssa Frank • October 2, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of August 2019.

By Molly Dee • September 27, 2019

The “Reject Due To” information contained in our online test catalog is being updated to provide greater clarity around rejection standards.

By Hannah Crawford • September 27, 2019

In August 2019, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • September 19, 2019

PD-L1 immunohistochemistry (IHC) is indicated in patients with specific tumor types in order to predict their responses to treatment with PD-L1 inhibitors. The specific PD-L1 clone, scoring method, and eligibility requirements are dependent on the tumor type, stage of malignancy, previous treatment outcomes, and specific PD-L1 inhibitor being considered.

By Alyssa Frank • September 15, 2019

With input from Mayo Clinic oncologists, our laboratories have developed a menu of next-generation sequencing (NGS) oncology panels. These panels aid in the diagnosis and management of patients with cancer and are optimized for clinically relevant genes and actionable targets consistent with current oncology guidelines.

By Alyssa Frank • September 1, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of July 2019.

By Molly Dee • August 27, 2019

In July 2019, Mayo Clinic Laboratories announced six new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • August 1, 2019

Ann Moyer, M.D., Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

By Emily Linginfelter • August 1, 2019

View a full list of new CPT codes, Test Classification Updates, LOINC Codes, and Z-Codes posted to mayocliniclabs.com during the month of June 2019.

By Andrew Tofilon • July 22, 2019

Antimicrobial susceptibility testing determines whether these bacteria are susceptible or resistant to a particular antibiotic. Bacteria are added onto plates of solid agar, where each plate has a different and increasing concentration of antibiotic than the previous plate. The minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial that inhibits growth of the bacteria.

By Christoph Bahn • July 22, 2019

In June 2019, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • July 18, 2019

David Viswanatha, M.D., a hematopathologist and co-director of the molecular hematology and complete genome sequencing laboratories at Mayo Clinic, provides an overview of BCR/ABL1 testing, discusses the best testing methods, NCCN/ELN criteria guidelines, why FISH testing is no longer routinely available at Mayo Clinic, and what test to order at what time for CML patients.

By Alyssa Frank • July 16, 2019